These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285 [TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515 [TBL] [Abstract][Full Text] [Related]
9. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Russell NH; Byrne JL; Faulkner RD; Gilyead M; Das-Gupta EP; Haynes AP Bone Marrow Transplant; 2005 Sep; 36(5):437-41. PubMed ID: 15980879 [TBL] [Abstract][Full Text] [Related]
10. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Lokhorst HM; Schattenberg A; Cornelissen JJ; van Oers MH; Fibbe W; Russell I; Donk NW; Verdonck LF J Clin Oncol; 2000 Aug; 18(16):3031-7. PubMed ID: 10944138 [TBL] [Abstract][Full Text] [Related]
11. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682 [TBL] [Abstract][Full Text] [Related]
12. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737 [TBL] [Abstract][Full Text] [Related]
14. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Klyuchnikov E; Holler E; Bornhäuser M; Kobbe G; Nagler A; Shimoni A; Könecke C; Wolschke C; Bacher U; Zander AR; Kröger N Br J Haematol; 2012 Oct; 159(2):172-81. PubMed ID: 22909192 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440 [TBL] [Abstract][Full Text] [Related]
16. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. Lokhorst HM; Segeren CM; Verdonck LF; van der Holt B; Raymakers R; van Oers MH; Barge RM; Schouten HC; Westveer PH; Steijaert MM; Cornelissen JJ; Sonneveld P; J Clin Oncol; 2003 May; 21(9):1728-33. PubMed ID: 12721248 [TBL] [Abstract][Full Text] [Related]